Australia markets close in 49 minutes

Grifols, S.A. (GIFLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
11.15+0.56 (+5.29%)
At close: 02:48PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.59
Open11.15
Bid0.00 x 0
Ask0.00 x 0
Day's range11.15 - 11.15
52-week range7.46 - 15.80
Volume250
Avg. volume2,096
Market cap6.5B
Beta (5Y monthly)0.67
PE ratio (TTM)111.50
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date03 June 2021
1y target estN/A
  • PR Newswire

    Grifols 2023 Annual Report on Form 20-F filed with the SEC

    Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the United States Securities and Exchange Commission ("SEC").

  • GlobeNewswire

    Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.

    The addition of the Clayton site in 2011 marked a new milestone for Grifols, turning the company into a top-three plasma industry leader and setting the stage for sustained business growth The flagship Grifols campus is a touchstone of Grifols’ leadership in plasma therapeutics, producing about 40% of the company’s total medicinal output globally and helping enhance the quality of life of patients all over the worldAn engineering masterwork, the Clayton site is a model for new Grifols plants whi

  • GlobeNewswire

    Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

    Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in climate and increasing global connectivity making the geographic spread more prevalent CE mark for Grifols’ Procleix ArboPlex Assay reinforces the company’s leadership in transfusion medicine and commitment to ensuring the safety of the world’s blood supply BARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE